[an error occurred while processing this directive]|[an error occurred while processing this directive]
局部进展期直肠癌新辅助放化疗的研究进展
王奕如, 张勇, 吴童, 沈梅竹
广西医科大学第一附属医院放疗科,南宁 530021
Research progresson neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Wang Yiru, Zhang Yong, Wu Tong, Shen Meizhu
Department of Radiation Oncology,First Affiliated Hospital of Guangxi Medical University,Radiation Oncology Clinical Medical Research Center of Guangxi,Nanning 530021,China
Abstract：Preoperative neoadjuvant chemoradiotherapy (NCR) combined with total mesorectal excision (TME) is the standard treatment mode for locally advanced rectal cancer. Compared with postoperative NCR, preoperative NCR increases the tumor down-staging, sphincter-preserving rate and local control rate. Patients who attain pathological complete response (pCR) after preoperative NCR have better prognosis compared with their counterparts. This article reviews the research progress on preoperative NCR in recent years.
Wang Yiru,Zhang Yong,Wu Tong et al. Research progresson neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 225-228.
[1] American Cancer Society. Cancer facts and figures 2016[M]. Atlanta:American Cancer Society,2016. [2] Carlson RW,Jonasch E. NCCN evidence blocks[J]. J Natl ComprCanc Netw,2016,14(5):616-619. DOI:10.6004/jnccn.2016.0177. [3] Bonadeo FA,Vaccaro CA,Benati ML,et al. Rectalcancer:local recurrence after surgery without radiotherapy[J]. Dis Colon Rectum,2001,44(3):374-379. DOI:10.1007/BF02234736. [4] Havenga K,DeRuiter MC,Enker WE,et al. Anatomical basis of autonomic nerve-preserving total mesorectal excision for rectal cancer[J]. Br J Surg,1996,83(3):383-384. [5] Masui H,Ike H,Yamaguchi S,et al. Male sexual function after autonomic nerve-preserving operation for rectal cancer[J]. Dis Colon Rectum,1996,39(10):1140-1145. [6] Maas M,Nelemans PJ,Valentini V,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J]. Lancet Oncol,2010,11(9):835-844. DOI:10.1016/s1470-2045(10)70172-8. [7] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Eng J Med,2004,351(17):1731-1740. DOI:10.1056/NEJMoa040694. [8] Ceelen W,Fierens K,VanNieuwenhove Y,et al. Preoperative chemoradiation versus radiation alone for stage Ⅱand stage Ⅲ Bresectable rectal cancer:a systematic review and meta-analysis[J]. Int J Cancer,2009,124(12):2966-2972. DOI:10.1002/ijc.24247. [9] Latkauskas T,Paskauskas S,Dambrauskas Z,et al. Preoperative chemoradiationvsradiation alonefor stage Ⅱand stage Ⅲ Bresectable rectal cancer:a meta-analysis[J]. Colorectal Dis,2009,12(11):1075-1083. DOI:1111/j.1463-1318.2009.02015.x. [10] De Caluwé L,Van Nieuwenhove Y. Preoperative chemoradiation versus radiation alonefor stage Ⅱ and stage ⅢBresectable rectal cancer[J]. The Cochrane database of systematic reviews,2013,(2):CD006041. DOI:10.1002/14651858. CD006041.pub3. [11] Kairevice L,Latkauskas T,Tamelis A,et al. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgeryfor stage Ⅱand stage ⅢBresectable rectal cancer:5-Year survival data of a randomized controlled trial[J]. Medicina,2017,53(3):150-158. DOI:10.1016/j.medici.2017.05.006. [12] Skóra T,Nowak-Sadzikowska J,Martyno′Bw D,et al. Preoperative short-course radiotherapy in rectal cancer patients:results and prognostic factors[J]. J Radiat Oncol,2018,7(1):77-84. DOI:10.1007/s13566-017-0340-5. [13] Garcia-Aguilar J,Chow OS,Smith DD,et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer:amulticentre,phase 2 trial[J]. Lancet Oncol,2015,16(8):957-966. DOI:10.1016/s1470-2045(15)00004-2. [14] Sainato A,Cernusco LNV,Valentini V,et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC):long term results of a randomized trial (I-CNR-RT)[J]. Radiother Oncol,2014,113(2):223-229. DOI:10.1016/j.radonc.2014.10.006. [15] Lefevre JH,Mineur L,Kotti S,et al. Effect of interval (7or11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer:amulticenter,randomized,controlled trial (GRECCAR-6)[J]. Clin Oncol,2016,34(31):3773-3780. DOI:10.1200/JCO.2016.67.6049. [16] Habr-Gama A,Perez RO,Proscurshim I,et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer:does delayed surgery have an impact on outcome[J]. Int JRadiat Oncol Biol Phys,2008,71(4):1181-1188.DOI:10. 1016 / j. ijrobp. 2007. 11. 035. [17] Bujko K,Wyrwicz A,Rutkowski M,et al. OC-0479 neoadjuvant chemoradiation fixed cT3 or cT4 rectal cancer:results of a phase Ⅲ study[J]. Radiat Oncol,2016,4(1):229-230. DOI:10.1016/S0167-8140(16)31728-5. [18] Fernandez-Martos C,Garcia-Albeniz X,Pericay C,et al. Chemoradiation,surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery:long-term results of the Spanish GCR-3 phase Ⅱ randomized trial[J]. Ann Oncol,2015,26(8):1722-1728. DOI:10.1093/annonc/mdv223. [19] Chua YJ,Barbachano Y,Cunningham D,et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer:a phase 2 trial[J]. LancetOncol,2010,11(3):241-248. DOI:10.1016/S1470-2045(09)70381-X. [20] Dewdney A,Cunningham D,Tabernero J,et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin,capecitabine,and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).[J]. J Clin Oncol,2012,30(14):1620-1627.DOI:10. 1200 / JCO. 2011. 39. 6036. [21] Sclafani F,Brown G,Cunningham D,et al. PAN-EX:a pooled analysis of 2 trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined,locally advanced rectal cancer[J]. Ann Oncol,2016,27(8):1557-1565. DOI:10.1093/annonc/mdw215. [22] Perez K,Safran H,Sikov W,et al. Complete neoadjuvant treatment for rectal cancer:the Brown University Oncology Group CONTRE study[J]. Am J Clin Oncol,2017,40(3):283-287. DOI:10.1097/COC.0000000000000149. [23] Dueland S,Ree AH,Groholt KK,et al. Oxaliplatin-containing preoperative therapy in locally advanced rectal cancer:localresponse,toxicity and long-term outcome[J]. Clin Oncol (R Coll Radiol),2016,28(8):532-539. DOI:10.1016/j.clon.2016.01.014. [24] Gao YH,An X,Sun WJ,et al. Evaluation of capecitabine and oxaliplatin aDministered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer[J]. J Surg Oncol,2014,109(5):478-482. DOI:10.1002/jso.23516. [25] Torok JA,Palta M,Willett CG,et al. Nonoperative management of rectal cancer[J]. Cancer,2016,122(1):34-41. DOI:10.1002/cncr.29735. [26] Ballonoff A,Kavanagh B,McCarter M,et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer:a phase Ⅱ trial[J]. Am J Clin Oncol,2008,31(3):264-270. DOI:10.1097/COC.0b013e318161dbd3. [27] Hernando-Requejo O,López M,Cubillo A,et al. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integerated-boost chemoradiation[J]. Strahlenther Onkol,2014,190(6):515-520. DOI:10.1007/s00066-014-0650-0. [28] Burbach JPM,den Harder AM,Intven M,et al. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer:a systemic review and meta-analysis[J]. Radiother Oncol,2014,113(1):1-9. DOI:10.1016/j.radonc.2014.08.035. [29] 刘景杰,张建军,赵文龙,等. 同步新辅助放化疗联合全根治性切除治疗中低位局部进展期直肠癌的探索研究[J]. 中国医学创新,2015,11(35):5-8.DOI:10. 3969 / j. issn.1674-4985. 2014. 33. 002. Liu JJ,Zng JJ,Zhao WL,et al. Neoadjuvant concurrent chemoradiotherapy combined with total mesorectal excision in the treatment of locally advanced middle and lower rectal cancer[J]. Med Innovat China,2015,11(33):5-8.DOI:10. 3969 / j. issn.1674-4985. 2014. 33. 002. [30] 刘其腾,冯春林,陈静,等. 局部中晚期直肠癌术前新辅助同期加量IMRT联合术前化疗的Ⅱ期临床研究[J]. 中华放射学肿瘤杂志,2017,26(3):302-306. DOI:10.3760/cma.j.issn.1004-4221.2017.03.011. Liu QT,Feng CL,Chen J,et al. Efficacy of preoperative neoadjuvant stimultaneous integrated boost intensity-modulated radiotherapy combined with preoperative chemotherapy for locally advanced rectal cancer:a phase Ⅱ clinical study[J]. Chin J Radiat Oncol,2017,26(3):302-306. DOI:10.3760/cma.j.issn.1004-4221.2017.03.011. [31] Yang YQ,Feng LC,Wang YL,et al. Adosimetric analysis of preoperative intensity-modulated and image-guided radiation therapy with and without simultaneous integrated boost for locally advanced rectal cancer[J]. Technol Cancer Res Treat,2015,14(5):557-563.DOI:10. 7785 / tcrt. 2012. 500442 [32] Engels B,Paoli AD,Cattari G,et al. Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiation therapy for T3-4 rectal cancer:interim analysis of a multicentric randomized trial[J]. Int J Radiat Oncol Biol Phys,2014,90:s22-s23. DOI:10.1016/j.ijrobp.2014.05.117. [33] Habr-Gama A,Perez RO,Nadalin W,et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy:long-term results[J]. Ann Surg,2004,240(4):711-717. DOI:10.1097/07.sla.0000141194.27992.32. [34] Habr-Gama A,Perez RO,Sabbaga J,et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer:results of a prospective study using additional chemotherapy during the resting period[J]. Dis Colon Rectum,2009,52(12):1927-1934. DOI:10.1007/DCR.0b013e3181ba14ed. [35] Habr-Gama A,Sabbaga J,Gama-Rodrigues J,et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer:are we getting closer to anal cancer management?[J]. Dis Colon Rectum,2013,56(10):1109-1117. DOI:10.1097/DCR.0b013e3182a25c4e. [36] Habr-Gama A,Perez RO,Sao Juliao GP,et al. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen[J]. J Radiat Oncol,2016,11(1):24. DOI:10.1186/s13014-016-0598-6.
2020, Vol. 29 
